VIDEO: OASIS study shows patient selection essential in ocriplasmin for VMT

CHICAGO — At the American Academy of Ophthalmology meeting here, Pravin U. Dugel, MD, discusses 2-year results of the OASIS study of ocriplasmin for vitreo-macular traction. “The key to this study is that a higher rate of success can be achieved with better patient selection, and no new safety signals were seen,” Dugel said.